Corient Private Wealth
AKRO

Corient Private Wealth’s Akero Therapeutics AKRO Stock Holding History

Corient Private Wealth’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-73,553
Closed -$3.92M – 2556
2025
Q2 		$3.92M Buy
+73,553
New +$3.34M 0.01% 783

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Corient Private Wealth's AKRO Position: Q3 2025 in Review

Corient Private Wealth sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 73,553 shares — an estimated $3.92M sold.

Corient Private Wealth first reported a position in AKRO in Q2 2025 and held it in 1 quarter. The position peaked at $3.92M in Q2 2025. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

  • Corient Private Wealth reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Corient Private Wealth sold 73,553 Akero Therapeutics shares in Q3 2025, an estimated $3.92M.
  • Corient Private Wealth first reported a position in Akero Therapeutics in Q2 2025 and held it in 1 quarter.
  • Corient Private Wealth's Akero Therapeutics position peaked at $3.92M in Q2 2025.
  • 265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on Corient Private Wealth's 13F filing for Q3 2025, filed 14 Nov 2025.